相关临床试验
1
0 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
1
100.0%
- All 24 patients with inoperable, locoregionally recurrent NSCLC completed radiotherapy-activated JNJ-1900 (NBTXR3) plus re-irradiation with no dose-limiting toxicities and no related Grade 3 or higher events. - At a median 12-month follow-up, one-year locoregional control reached 79%, one-year local progression-free survival 61% and one-year overall survival 70%. - Investigators concluded the hafnium oxide nanoparticle radioenhancer may permit clinically meaningful local control at a substantially lower re-irradiation dose than patients' prior radiotherapy course. - Enrollment in the dose-escalation and expansion phases is complete per protocol, and additional patients are now planned following the encouraging findings.
- Researchers at UT MD Anderson found that, in preclinical models of colorectal cancer, tumors can damage peripheral nerves before any chemotherapy is given. - The nerve damage affects the protective myelin insulation and is largely latent, occurring without obvious pain symptoms, yet may affect survivors' quality of life. - Tumor-driven inflammation and altered fat metabolism appear to contribute to nerve stress and damage, though inflammation is not the only factor involved. - The findings challenge the assumption that peripheral neuropathy in colorectal cancer patients stems mostly from chemotherapy, but human studies are still needed.
- Adult survivors of Hodgkin lymphoma had nearly twice the mortality of the general U.S. population, with a standardized mortality ratio of 1.96 (95% CI: 1.89–2.03). - The study analyzed 20,057 long-term survivors diagnosed between 2000 and 2017, observing 2,899 deaths versus 1,480.8 expected. - While malignant conditions drove relative mortality risk, cardiovascular and other noncancer causes accounted for the greatest absolute excess in deaths. - Findings underscore the need for lifelong survivorship care focused on cardiovascular health, secondary cancers, and other chronic conditions.
- A Nature study analyzing the Phase 3 CheckMate 77T trial found that ctDNA clearance before surgery and pathologic complete response are the strongest indicators of positive outcomes in resectable NSCLC. - Patients receiving perioperative nivolumab were nearly twice as likely to clear ctDNA before surgery (66% vs. 38%) and more likely to achieve pathologic complete response (50% vs. 12%) compared with placebo. - All 13 patients who converted from MRD-negative to MRD-positive after surgery subsequently developed disease recurrence, establishing postoperative ctDNA as a strong prognostic signal. - The findings are exploratory and require additional research before blood-based biomarkers can be routinely used to guide clinical practice.
- A new MD Anderson study published in Cancer Immunology Research shows that inflammatory arthritis after immune checkpoint inhibitor therapy behaves like an immune-memory disease. - Researchers identified two persistent immune cell populations — inflammatory CD8 T cells and PD-1/CXCL13 co-expressing CD4 T cells — present in both initial and recurrent arthritis flares. - Approximately 20% to 50% of patients who develop this side effect experience recurrence, with subsequent flares often more severe than initial episodes. - The findings suggest these immune cell populations could serve as biomarkers to identify high-risk patients and guide targeted therapies that suppress arthritis without compromising anti-tumor immunity.
- The Society of Hematologic Oncology (SOHO) has launched its second podcast, SOHO Spotlight, focused on educational content for hematologic malignancy management. - The podcast features leading global experts sharing practical tips and strategies on leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. - The inaugural episode features Dr. Jae Park and Dr. Nicholas Short discussing CAR T-cell therapy, including safer outpatient treatment and earlier lines of treatment. - Episodes are available on major platforms including Spotify, Amazon, YouTube, and Apple Podcasts.
- A preclinical study from MD Anderson Cancer Center reveals that cuproptosis, a copper-induced form of cell death, can actively engage the immune system and enhance antitumor responses. - Researchers identified a reinforcing two-way interaction in which CD8-positive T cells promote cuproptosis in cancer cells, and cuproptosis in turn stimulates stronger immune responses. - Combining cuproptosis-inducing agents with anti-PD-L1 immunotherapy significantly slowed tumor growth, even in models resistant to immunotherapy alone. - The FDX1 gene may serve as a biomarker to identify patients most likely to benefit from this combination strategy, and the agents used already have clinical experience with favorable safety profiles.
- A phase II trial demonstrated that 53% of carefully selected early-stage breast cancer patients achieved pathologic complete response with ablative radiation therapy and endocrine therapy, allowing them to omit surgery entirely. - Patients who avoided surgery maintained 100% disease control with no breast cancer-related deaths at a median follow-up of over three years, suggesting non-operative approaches may be viable for select cases. - Key biomarkers including smaller tumor size after hormone therapy, greater volume reduction before radiation, and stronger estrogen receptor expression predicted complete responses to treatment. - The findings represent a potential paradigm shift in breast cancer treatment de-escalation, moving beyond reducing therapy duration to exploring entirely non-operative approaches for appropriate patients.
- A phase I clinical trial demonstrated that intralesional nivolumab injection reduced precancerous oral lesion size by an average of 60% in 85% of patients, allowing many to avoid surgery. - The treatment used only 2-4% of the standard intravenous dose, resulting in 10-fold lower serum levels and minimal systemic toxicity compared to systemic administration. - After 14.5 months median follow-up, 82.13% of treated lesions remained cancer-free, with six patients achieving complete pathologic response. - The approach preserved quality of life and oral function while demonstrating immune activation exclusively in treated lesions, suggesting potential applications for other precancerous conditions.
- Lirum Therapeutics announced positive preclinical data for LX-101, a novel IGF-1R-targeted therapy, demonstrating potent antitumor activity in Ewing sarcoma patient-derived xenograft models. - The therapy showed improved activity compared to previously reported IGF-1R-targeting approaches and demonstrated synergy when combined with PI3K or mTOR inhibitors. - The FDA has issued a "Study May Proceed" letter allowing LX-101's inclusion in the RAPID platform trial for patients with relapsed/refractory Ewing sarcoma and desmoplastic small round cell tumor. - The data will be presented at the 2026 AACR Annual Meeting, highlighting the strong scientific rationale for targeting IGF-1R in Ewing sarcoma due to DNA-level gene fusions affecting this pathway.
